Navigation Links
CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
Date:9/4/2007

LAGUNA HILLS, Calif., Sept. 4 /PRNewswire/ -- CODA Genomics, Inc., a pioneer in applying its namesake technology, (Computational Optimized DNA Assembly) towards the manufacture of synthetic genes and other DNA fragments, announced today that the US Patent and Trademark Office has issued US Patent 7,262,031 to its two founding scientists, University of California, Irvine (UCI) professors, Richard H. Lathrop and G. Wesley Hatfield. The technology was developed under a prestigious Information Technology Research grant from the National Science Foundation jointly in the School of Medicine and the Donald Bren School of Information and Computer Sciences at UCI. The Company has licensed this patent exclusively from the UCI's Office of Technology Assessment (OTA).

US Patent 7,262,031 entitled, "Method for Producing a Synthetic Gene or Other DNA Sequence," teaches how to use a global (across all possible correct and incorrect gene assemblies) optimization method for the choice of DNA code to make a given protein. Properly chosen DNA enables the thermodynamically controlled self-assembly of only the desired DNA product(s). The synthetic gene is simultaneously optimized for many other parameters that affect the successful use of the gene to make protein efficiently in any desired biological system.

Dr. Robert J Molinari, Ph.D., CODA's CEO said, "This broad protection of CODA's breakthrough technology will allow the company to aggressively market its high-yielding Hot-RodTM genes, and other optimized gene variant sets. For the customer, it allows a scaleable way to test a large number of gene and protein variants for desirable properties."

David Schetter, assistant Vice-chancellor, Research and Technology Alliances, at UCI adds "CODA has been one of UCI's first, successful examples of OTA's "Virtual Incubation" model where early stage technology is licensed to a start-up company and the technology is incubated in the University by way of a series of standard agreements for research, technology development and access to UCI's facilities and equipment. All of these agreements are negotiated at arm's length and meet the university's standards for proper use of university facilities and mitigation of conflicts of interest. As a result, the University gains additional resources and a role in ensuring the success of the technology while the company does not incur premature and expensive spin-out costs. Additionally, with more well developed and proven technology, the company is better able to raise required capital to move to its non-virtual stage."

About CODA Genomics, Inc.

CODA Genomics, Inc. is a protein Translation Engineering company focused on proprietary patented approaches to express proteins in a variety of organisms. This unique technology enables synthetic biology to solve many protein expression problems. For more CODA information, visit http://www.codagenomics.com.


'/>"/>
SOURCE CODA Genomics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. The DIG System Nonradioactive Automated High-Throughput In Situ Hybridization: a Powerful Tool for Functional Genomics Research
2. Genomics researcher Hood joins NimbleGen board
3. GE Healthcare partners with genomics institute
4. Speaker announces business members of IT Task Force
5. Doyle announces technology tax credits for Berbee
6. Doyle announces new energy, global warming policies
7. Doyle announces $80M renewable energy strategy
8. GE announces first installation of Discovery VCT
9. UWM announces winners of RGI awards
10. Third Wave announces two senior management appointments
11. Mirus announces new method for making antibodies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , ... October 11, 2017 , ... ... (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer ... treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and bind ...
(Date:10/10/2017)... Angeles, CA (PRWEB) , ... ... ... Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, ... uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder ... local San Diego Rotary Club. The event entitled “Stem Cells and ... had 300+ attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: ...
(Date:10/10/2017)... 2017 SomaGenics announced the receipt of a ... RealSeq®-SC (Single Cell), expected to be the first commercially ... microRNAs) from single cells using NGS methods. The NIH,s ... accelerate development of approaches to analyze the heterogeneity of ... techniques for measuring levels of mRNAs in individual cells ...
Breaking Biology Technology:
(Date:7/20/2017)... 20, 2017 Delta (NYSE: DAL ) customers now ... aircraft at Reagan Washington National Airport (DCA). ... Delta launches biometrics to board aircraft at ... Delta,s biometric boarding pass experience ... is now integrated into the boarding process to allow eligible Delta SkyMiles ...
(Date:6/14/2017)...  IBM (NYSE: IBM ) is introducing several innovative ... to developing collaboration between startups and global businesses, taking place ... the event, nine startups will showcase the solutions they have ... France is one ... a 30 percent increase in the number of startups created ...
(Date:5/16/2017)... DALLAS , May 16, 2017   ... for health organizations, and MD EMR Systems ... certified development partner for GE, have established a ... Patient Portal product and the GE Centricity™ products, ... Centricity EMR. These new integrations ...
Breaking Biology News(10 mins):